Janssen's Rybrevant, which is conducting a combined clinical trial with Leclaza, a new non-small cell lung cancer treatment drug developed by Yuhan Corporation, has been approved in Korea.

The MFDS approved Janssen's Rybrevant on the 15th. This drug is used for "the treatment of patients with local progressive and metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 20 insertion mutations in which the disease progressed during or after platinum-based chemotherapy." The recommended dosage also varies depending on the patient's weight with intravenous injections.

The drug is drawing particular attention because it is conducting clinical trials in combinati